The treatment backbone for Ph+ ALL is shifting away from intensive chemotherapy like hyper-CVAD. Chemotherapy-free regimens combining blinatumomab with a TKI (preferably ponatinib) are becoming the new standard, showing outcomes that are at least as good as, and likely better than, traditional chemotherapy.

The DREAM-7 trial showed a belantumab combination had an overall survival benefit versus a daratumumab regimen, a "premier drug" that previously changed the myeloma treatment landscape. This surprising result establishes a new, higher standard of care and positions belantumab as a top-tier therapy, not merely another option.

In the Podium-303 trial, adding retifanlimab to chemotherapy improved the overall response rate by 11%. However, its most significant impact was doubling the median duration of response from 7.2 to 14 months, providing a much more durable benefit for patients after chemotherapy is stopped.

While blinatumomab-TKI combinations avoid systemic chemotherapy toxicity, they are associated with higher rates of central nervous system (CNS) relapses. This necessitates an increased number of intrathecal chemotherapy doses to prevent CNS disease, a critical nuance for managing this 'simpler' approach.

Data from trials like CheckMate 816 shows that achieving a Pathologic Complete Response (PCR) after neoadjuvant chemo-immunotherapy is a powerful early surrogate endpoint. Patients with PCR demonstrate markedly improved overall and event-free survival.

The regimen's profound success in relapsed/refractory patients is not an endpoint, but a launchpad. It provides the rationale for the ongoing Epcor FL2 trial, which directly challenges standard chemoimmunotherapy and could establish a chemotherapy-free, bispecific-based combination as the new first-line standard of care.

The subcutaneous formulation of blinatumomab is more than a convenience upgrade. It allows for safely achieving higher steady-state drug concentrations compared to the continuous IV infusion. This improved pharmacokinetic profile translates directly into superior efficacy, particularly in patients with high tumor burdens.

The long-standing platinum doublet backbone for frontline SCLC may soon be challenged. The high efficacy of novel agents like antibody-drug conjugates and bispecific antibodies in later lines is prompting trials that consider moving them into the first-line setting, a strategy previously considered "unthinkable."

A key lesson in bladder cancer is that patient attrition is rapid between lines of therapy; many who relapse from localized disease never receive effective later-line treatments. This reality provides a strong rationale for moving the most effective therapies, like EV-pembrolizumab, to earlier settings to maximize the number of patients who can benefit.